News & Press


MRF & MRA Commend the Senate Appropriations Committee for Including $30 million for Defense-Funded Melanoma Research in FY2021 Bill

December 1, 2020

Washington, DC – The Melanoma Research Alliance (MRA) and the Melanoma Research Foundation (MRF) commend the Senate Appropriations Committee for including $30 million for Department of Defense-funded melanoma research in the Fiscal 2021 Department of D …



FDA Approves Foundation Medicine’s FoundationOne Liquid CDx, a Comprehensive Pan-Tumor Liquid Biopsy Test

August 28, 2020

Washington, DC, August 28, 2020 – This week, the U.S. Food and Drug Administration (FDA) approved Foundation Medicine, Inc.’s comprehensive pan-tumor liquid biopsy test called FoundationOne Liquid CDx. This test analyzes more than 300 genes and genomic …



FDA Approves Atezolizumab to Treat BRAF V600 Unresectable or Metastatic Melanoma

July 31, 2020

Washington, DC, July 31, 2020 – On July 30, 2020, the Food and Drug Administration approved atezolizumab (Tecentriq, Genentech, Inc.) in combination with cobimetinib and vemurafenib for the treatment of patients with BRAF V600 mutation-positive unresec …



House Appropriations Committee Includes $20 million for Defense-funded Melanoma Research

July 21, 2020

Washington, DC, July 21, 2020 – The Melanoma Research Foundation (MRF) commends the House Appropriations Committee for including $20 million for Department of Defense (DoD)-funded melanoma research in its Fiscal 2021 Department of Defense Appropriation …



House Appropriations Committee Approves Funding for Fiscal 2021 Labor, Health and Human Services Bill

July 13, 2020

Washington, DC, July 13, 2020 – Today the House Appropriations Committee approved its version of the Fiscal 2021 Labor, Health and Human Services (LHHS) Appropriations bill. The House bill provides $47 billion for the National Institutes of Health (NIH …